Atea Pharmaceuticals, Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDAtea Pharmaceuticals, Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 85), indicating clear outperformance against the broad market. Earnings contraction of 43% provides fundamental context to the price action. However, price is extended 20% above the 50-day line, increasing the risk of a mean reversion.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $4.38 | +6.79% | ABOVE |
| 50 SMA | $3.89 | +20.17% | ABOVE |
| 100 SMA | $3.52 | +32.78% | ABOVE |
| 150 SMA | $3.45 | +35.68% | ABOVE |
| 200 SMA | $3.41 | +37.25% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is AVIR in an uptrend right now?
AVIR has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, AVIR is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is AVIR overbought or oversold?
AVIR's RSI (14) is 67. The stock is in neutral territory, neither overbought nor oversold.
Is AVIR outperforming the market?
AVIR has a Relative Strength (RS) Rating of 85 out of 99. Yes, AVIR is a market leader, outperforming 85% of all stocks over the past 12 months.
Where is AVIR in its 52-week range?
AVIR is trading at $4.68, which is 98% of its 52-week high ($4.80) and 95% above its 52-week low ($2.46).
How volatile is AVIR?
AVIR has a Beta of 0.64 and 52-week volatility of 46%. It's less volatile than the S&P 500 - generally more stable.